TITLE

New angiotensin-receptor blocker approved by FDA

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
April 2011
SOURCE
American Journal of Health-System Pharmacy;4/1/2011, Vol. 68 Issue 7, p550
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on azilsartan medoxomil, an angiotensin-receptor blocker to be marketed as "Edarbi" by Takeda Pharmaceuticals North America Inc., which has been approved by the Food and Drug Administration (FDA) for the treatment of hypertension.
ACCESSION #
59967700

 

Related Articles

  • FDA approves sacubitril/valsartan to treat heart failure. Marshall, Jennifer L.; Chamberlin, Kevin W. // Drug Topics;Nov2015, Vol. 159 Issue 11, p34 

    The article discusses U.S. Food and Drug Administration's (FDA) approval of sacubitril/valsatran (Entresto; Novartis) for the treatment of heart failure with reduced ejection fraction. Entresto's approval was based on PARADIGM-HF, a multi-phase clinical study that included a double blind 1:1...

  • NEWS.  // Clarendon Enterprise (TX);12/5/2013, Vol. 24 Issue 49, p5 

    The article offers brief information on the drug macitentan with the brand name Opsumit which has been approved by the U.S. Food and Drug Administration for the treatment of pulmonary arterial hypertension (PAH) in adults.

  • FDA advisory panel favors approval of riociguat. Swain, Erik // Cardiology Today;Sep2013, Vol. 16 Issue 9, p16 

    The article focuses on the recommendation given by the Cardiovascular and Renal Drugs Advisory Committee of the U.S. Food & Drug Administration (FDA), on August 2013, to approve the use of riociguat for treatment of patients with pulmonary arterial hypertension and patients with chronic...

  • New Triple Therapy for Hypertension Approved.  // Clarendon Enterprise (TX);2/ 3/2011, Vol. 22 Issue 8, p8 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved a new triple therapy medication called Amturnide, which can be used for the treatment of hypertension through the combination of a calcium channel blocker, a renin inhibitor, and a diuretic.

  • Liquid Form of Enalapril Now Available.  // MPR - Pediatricians' Edition;Fall/Winter2013, Vol. 24 Issue 2, pA6 

    The article reports on the approval of Epaned Powder for Oral Solution by the U.S. Food and Drug Administration (FDA) to treat hypertension in patients not more than or equal to 1 month old.

  • FDA O.K.'s Daiichi Sankyo's Benicar.  // Chain Drug Review;3/15/2010, Vol. 32 Issue 6, p84 

    The article reports on the approval of the drug Benicar as hypertension treatment from Daiichi Sankyo Inc. by the U.S. Food and Drugs Administration.

  • First In A New Class Of Drugs For Treating Hypertension.  // RN;Jan2003, Vol. 66 Issue 1, p93 

    The article reports on the U.S. Food and Drug Administration's approval of eplerenone, a cardiovascular agent for treating patients with high blood pressure, by the U.S. Food and Drug Administration. The new drug can selectively block receptors of aldosterone which cause the development and...

  • DRUG APPROVED TO TREAT PULMONARY HYPERTENSION.  // Medical Economics;12/25/2103, Vol. 90 Issue 24, p19 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved riociguat (Adempas) tablets for treating chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) in adults and the drug can overcome nitric oxide (NO) dependence.

  • Erratum to: ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients. Volpe, Massimo; Sierra, Alejandro; Kreutz, Reinhold; Laurent, Stéphane; Manolis, Athanasios // High Blood Pressure & Cardiovascular Prevention;Jun2014, Vol. 21 Issue 2, p149 

    A correction to the article "ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients" that was published online on March 29, 2014 is presented.

  • FDA officials disagree about the safety of ARBs. Mccarthy, Mike // BMJ: British Medical Journal;6/15/2013, Vol. 346 Issue 7912, p6 

    The article reports on the debate between the U.S. Food and Drug Administration (FDA) and Thomas A Marciniak, a senior safety reviewer at the FDA, over the availability of adequate evidence to suggest an association between angiotensin receptor blockers (ARBs) and an increased risk of lung cancer.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics